MHC class II presentation of human acetylcholine receptor in Myasthenia gravis: Binding of synthetic gamma subunit sequences to DR molecules

Journal of Autoimmunity

Volumn 9, Issue 1, 1996, Pages 67-77

  Yuen, Mi Ha ^a   Macklin, Kevin D ^a   Conti Fine, Bianca M ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Acetylcholine receptor; CD4+ T cell epitopes; DR binding; Myasthenia gravis

Indexed keywords

AUTOANTIGEN; CD4 ANTIGEN; CHOLINERGIC RECEPTOR; HLA DR ANTIGEN; SYNTHETIC PEPTIDE;

ANTIGEN PRESENTATION; ARTICLE; HUMAN; HUMAN CELL; MYASTHENIA GRAVIS; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0029916221     PISSN: 08968411     EISSN: None     Source Type: Journal    
DOI: 10.1006/jaut.1996.0009     Document Type: Article

References (51)

1. Drachman D.B. 1994. Myasthenia gravis. New England J. Med. 330: 1797-1810
2. Protti M.P., Manfredi A.A., Horton R.M., Bellone M., Conti-Tronconi B.M. 1993. Myasthenia gravis: recognition of a human autoantigen at the molecular level. Immunol. Today 14: 363-368
3. Mishina M., Takai T., Imoto K., Noda M., Takahashi T., Numa S. et al. 1986. Molecular distinction between fetal and adult forms of muscle acetylcholine receptor. Nature 321: 406-411
4. Gu Y., Hall Z.W. 1988. Immunological evidence for a change in subunits of the acetylcholine receptor in developing and denervated rat muscle. Neuron 1: 117-125
5. Conti-Fine B.M., McLane K.E., Raftery M.A., Grando S.A., Protti M.P. 1994. The nicotinic acetylcholine receptor: structure and autoimmune pathology. CRC Crit. Rev. in Biochem. and Molec. Biol. 29: 69-123
6. Nelson S., Conti-Tronconi B.M. 1990. Adult thymus expresses an embryonic nicotinic acetylcholine receptor-like protein. J. Neuroimmunol. 29: 81-92
7. Hohlfeld R., Wekerle H. 1994. The thymus in myasthenia gravis. Neurologic. Clinic. 12: 331-342
8. Melms A., Chrestel S., Schalke B.C.G., Wekerle H., Mauron A., Ballivet M. et al. 1988. Autoimmune T lymphocytes in myasthenia gravis: determination of target epitopes using T lines and recombinant products of the mouse nicotinic acetylcholine receptor gene. J. Clin. Invest. 83: 285-289
9. Lisak R.P., Levinson A.I., Zweiman B., Kornstein M.J. 1986. Antibodies to acetylcholine receptor and tetanus toxoid: in vitro synthesis by thymic lymphocytes. J. Immunol. 1376: 1221-1225
10. Schöenbeck S., Padberg F., Hohlfeld R., Wekerle H. 1992. Transplantation of thymic autoimmune microenvironment to severe combined immunodeficiency mice. J. Clin. Invest. 90: 245-250
11. Weinberg C.B., Hall Z.W. 1979. Antibody from patients with myasthenia gravis recognize determinants unique to extrajunctional acetylcholine receptors. Proc. Natl. Acad. Sci. USA 76: 504-508
12. Protti M.P., Manfredi A.A., Howard J.F. Jr., Conti-Tronconi B.M. 1991. T cells in myasthenia gravis specific for embryonic muscle acetylcholine receptor. Neurology 41: 1809-1814
13. + T epitopes on the embryonic γ subunit of human muscle acetylcholine receptor. J. Clin. Invest. 90: 1558-1567
14. Manfredi A.A., Protti M.P., Wu X.D., Howard J.F. Jr., Conti-Tronconi B.M. 1993. Myasthenia gravis: epitopes recognized by autoimmune Th cells on the γ and δ subunit of the muscle acetylcholine receptor. J. Clin. Invest. 92: 1055-1067
15. Kaminski H.J., Maas E., Spiegel P., Ruff R.L. 1990. Why are eye muscles frequently involved in myasthenia gravis? Neurology 40: 1663-1669
16. Horton R.M., Manfredi A.A., Conti-Tronconi B.M. 1993. The 'embryonic' gamma subunit of the nicotinic acetylcholine receptor is expressed in adult extraocular muscle. Neurology 43: 983-986
17. Hohlfeld R., Conti-Tronconi B.M., Kalies I., Bertrams J., Toyka K.V. 1985. Genetic restriction of autoreactive acetylcholine receptor-specific T lymphocytes in Myasthenia Gravis. J. Immunol. 135: 2393-2399
18. Melms A., Malcherek G., Gern U., Wietholter H., Muller C.A., Schoepfer R. et al. 1992. T cells from normal and myasthenic individuals recognize the human acetylcholine receptor: heterogeneity of antigenic sites on the α-subunit. Ann. Neurol. 31: 311-318
19. + epitopes. J. Immunol. 152: 4686-4698
20. + lymphocytes by soluble major histocompatibility complex class II-peptide complexes. J. Clin. Invest. 93: 1361-1369
21. Manfredi A.A., Yuen M.H., Moiola L., Maria P.P., Conti-Tronconi B.M. 1994. Human acetylcholine receptor presentation in Myasthenia gravis: DR restriction of autoimmune T epitopes and binding of synthetic receptor sequences to DR molecules. J. Immunol. 152: 4165-4174
22. O'Sullivan D., Sidney J., Appella E., Walker L., Phillips L., Colon S.M. et al. 1990. Characterization of the specificity of peptide binding to four DR haplotypes. J. Immunol. 145: 1799-1808
23. Schild H., Rotzschke O., Kalbacher H., Rammensee H.-G. 1990. Limit of T cell tolerance to self protein by peptide presentation. Science 247: 1587-1589
24. Brown J.H., Jardetzky T.S., Gorga J.C., Stern L.J., Urban R.G., Strominger J.L. et al. 1993. Three-dimensional structure of the human class I histocompatibility antigen HLA-DR1. Nature 364: 33-39
25. Stern L.J., Brown J.H., Jardetzky T.S., Gorga J.C., Urban R.G., Strominger J.L. et al. 1994. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 368: 215-221
26. Laemmli U.K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685
27. Shibahara S., Kubo T., Perski H.J., Takahashi H., Noda M., Numa S. 1985. Cloning and sequence analysis of human genomic DNA encoding the γ subunit precursor of muscle acetylcholine receptor. Eur. J. Biochem. 146: 15-21
28. Houghten R.A. 1985. General method for the rapid solid phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids. Proc. Natl. Acad. Sci. USA 82: 5131-5135
29. Valmori D., Pessi A., Bianchi E., Corradin G. 1992. Use of universally antigenic tetanus toxin T cell epitopes as carriers for human vaccination. J. Immunol. 149: 717-721
30. O'Sullivan D., Arrhenius T., Sidney J., Del Guercio M.-F., Albertson M., Wall M. et al. 1991. On the interaction of promiscuous antigenic peptides with different DR alleles. J. Immunol. 147: 2663-2669
31. Manfredi A.A., Yuen M.-H., Raftery M.A., Conti-Tronconi B.M. 1993. An assay for simultaneous multiple determination of peptide binding to MHC class II molecules. Anal. Biochem. 211: 267-273
32. Rudensky A.Y., Preston-Hurlburt P., Soon-Cheol H., Barlow A., Janeway C.A. Jr. 1991. Sequence analysis of peptide bound to MHC class II molecules. Nature 353: 622-627
33. Chicz R.M., Urban R.G., Gorga J.C., Vignali D.A.A., Lane W.S., Strominger J.L. 1993. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J. Exp. Med. 178: 27-47
34. Vacchio M.S., Berzofsky J.A., Krzych U., Smith J.A., Hodes R.J., Finnegan A. 1989. Sequences outside a minimal immunodominant site exert negative effects on recognition by staphylococcal nuclease-specific T cell clones. J. Immunol. 143: 2814-2819
35. Chicz R.M., Urban R.G., Lane W.S., Gorga J.C., Stern L.J., Vignali D.A.A. et al. 1992. Predominant naturally processed peptides bound to HLA DR1 are derived from MHC-related molecules and are heterogeneous in size. Nature 358: 764-768
36. O'Sullivan D., Sidney J., Del Guercio M.-F., Colon S.M., Sette A. 1991. Truncation analysis of several DR binding epitopes. J. Immunol. 146: 1240-1246
37. Gammon G., Sercarz E. 1989. How some T cells escape tolerance induction. Nature 342: 183-185
38. Fairchild P.J., Wildgoose R., Atherton E., Webb S., Wraith D.C. 1993. An autoantigenic T cell epitope forms unstable complexes with class II MHC: A novel route for escape from tolerance induction. International Immunol. 5: 1151-1158
39. Salvetti M., Jung S., Chang S.-F., Will H., Schalke B.C.G., Wekerle H. 1991. Acetylcholine receptor specific T lymphocyte clones in the normal human immune repertoire: target epitopes, HLA restriction, and membrane phenotypes. Ann. Neurol. 29: 508-516
40. Protti M.P., Manfredi A.A., Wu X.D., Moiola L., Howard J.F. Jr., Conti-Tronconi B.M. 1991. Myasthenia gravis: T epitopes of the δ subunit of human muscle acetylcholine receptor. J. Immunol. 146: 2253-2261
41. + cells of myasthenia gravis patients and healthy subjects. J. Clin. Invest. 93: 1020-1028
42. Newcombe J.R., Cresswell P. 1993. Characterization of endogenous peptides bound to purified HLA-DR molecules and their absence from invariant chain-associated αβ dimers. J. Immunol. 150: 499-507
43. Sette A., Sidney J., Oseroff C., del Guercio M.-F., Southwood S., Arrhenius T. et al. 1993. HLA DR4w4-binding motifs illustrate the biochemical basis of degeneracy and specificity in peptide-DR interactions. J. Immunol. 151: 3163-3170
44. Hammer J., Takacs B., Sinigaglia E 1992. Identification of a motif for HLA-DR1 binding peptides using M13 display libraries. J. Exp. Med. 176: 1007-1013
45. Hammer J., Valsasnini P., Tolba K., Bolin D., Higelin J., Takacs B., Sinigaglia F. 1993. Promiscuous and allele-specific anchors in HLA-DR-binding peptides. Cell 74: 197-203
46. Kurata A., Berzofsky J.A. 1990. Analysis of peptide residues interacting with MHC molecule or T cell receptor. Can a peptide bind in more than one way to the same MHC molecule? J. Immunol. 144: 4526-4535
47. Malcherek G., Gnau V., Jung G., Rammensee H.-G., Melms A. 1995. Supermotifs enable natural invariant chain-derived peptides to interact with many major histocompatibility complex-class II molecules. J. Exp. Med. 181: 527-536
48. Sette A., Southwood S., Miller J., Appella E. 1995. Binding of major histocompatibility complex class II to the invariant chain-derived peptide, CLIP, is regulated by allelic polymorphism in class II. J. Exp. Med. 181: 677-683
49. Roche P.A., Cresswell P. 1990. High-affinity binding of an influence hemagglutinin-derived peptide to purified HLA-DR. J. Immunol. 144: 1849-1856
50. Malcherek G., Gnau V., Stevanovic S., Rammensee H.-G., Jung G., Melms A. 1994. Analysis of allele-specific contact sites of natural HLA-DR17 ligands. J. Immunol. 153: 1141-1149
51. Hammer J., Bono E., Gallazzi F., Belunis C., Nagy Z., Sinigaglia F. 1994. Precise prediction of major histocompatibility complex class II-peptide interaction based on peptide side chain scanning. J. Exp. Med. 180: 2353-2358